Skip to main content
. 2020 Dec 31;9(12):6023–6040. doi: 10.4103/jfmpc.jfmpc_1060_20

Table 3.

AzCERT classification, and therapeutic classes of drugs involved in QT-interval prolonging drug-drug interactions in elderly patients

Classification scheme n (interacting drugs) %a
AzCERT classification
 Known risk of TdP (List 1) 254 48.8
 Possible risk of TdP (List 2) 181 34.8
 Conditional risk of TdP (List 3) 62 12.0
 Not included in AzCERT QT drugs lists (List 4)b 23 4.4
Therapeutic categories
 Antidepressant (N06A) 144 27.7
 Proton pump inhibitor (A02BC) 91 17.5
 Antipsychotic (N05A) 85 16.3
 Antinausea (A04AA) 46 8.8
 Antimicrobial (J01MA/J01FA) 39 7.5
 H2-Receptor Antagonist (A02BA01/02/03) 15 2.9
 Antihistamine (R06AD) 12 2.3
 Anticonvulsant (N03AX11) 10 1.9
 Antidementia (N06D) 10 1.9
 Diuretics (C03) 10 1.9
 Antineoplastic & immunomodulating agents (L01/L02/L03) 8 1.5
 Antimalarial (P01B) 6 1.2
 Antifungal (D01AC) 5 1.0
 Calcium channel blocker (C08CA01) 5 1.0
 Antituberculars (J04A) 5 1.0
 Antidiabetics (A10A/A10B) 5 1.0
 Beta blocking agents (C07A) 4 0.8
 Antiarrhythmics (C01B/C01E) 4 0.8
 Drugs for airway obstructive diseases (R03) 3 0.6
 Antivirals (J05A) 3 0.6
 Platelet aggregation inhibitors (B01AC) 2 0.4
 Lipid modifying agents (C10A/C10B) 2 0.4
 Antithyroid(H03B) 1 0.2
 Antiparkinsonian Drugs(N04) 1 0.2
 Drugs for BPH(G04C) 1 0.2
 Agents acting on Renin Angiotensin system (C09) 1 0.2

AzCERT=Arizona Center for Education and Research on Therapeutics (CredibleMeds); TdP=Torsades de Pointes; Total number of QT-interval prolonging drug-drug interactions i.e., 288; aPercentage calculated from number of all interacting drugs i.e., 520; b“Not included in AzCERT QT drugs lists (List 4)” = Total number of drugs to avoid in congenital long QT (List 4) = 18 (including 3 two-drug combinations); This list contains drugs exclusively from List 4; overlapping drugs from CredibleMeds Lists 1-3 have been excluded